Cytospire Secures $83M for Cancer Engagers
May 5, 2026
London biotech Cytospire raised £61M ($83M) to advance pan-gamma delta T-cell engagers, led by CYT X300 for EGFR-positive solid tumours.
May 5, 2026
London biotech Cytospire raised £61M ($83M) to advance pan-gamma delta T-cell engagers, led by CYT X300 for EGFR-positive solid tumours.